Epigenic Therapeutics has successfully completed a $60 million Series B financing round to advance its clinical drug development and technology platforms in epigenetic medicine.
Target Information
Epigenic Therapeutics, established in 2021, is a pioneering biotechnology company focused on the innovative development of gene modulation therapies utilizing epigenetic regulation. The company is at the forefront of epigenetic medicine and has developed its proprietary technology platforms, including EPIREG™ for gene silencing and EpiTax™ for delivery. These platforms allow Epigenic to address prevalent diseases through precise therapeutic interventions, leading to enhanced safety compared to traditional gene-editing methods.
The company is currently advancing its clinical programs, notably EPI-003 aimed at a functional cure for chronic hepatitis B and EPI-001 targeting hypercholesterolemia treatments. With a strong pipeline of therapies for various diseases such as metabolic, cardiovascular, viral hepatitis, and autoimmune disorders, Epigenic is poised to make significant contributions to the medical field.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Biotechnology Sector
The biotechnology industry, particularly in the United States, has experienced robust growth due to increasing advancements in precision medicine, genetic research, and patient-centric therapies. The focus on epigenetics, in particular, represents a transformative shif
Similar Deals
Lapam Capital
invested in
Epigenic Therapeutics
in 2025
in a Series B deal
Disclosed details
Transaction Size: $60M